Pharmaceutical | Page 38 of 46

Health :: Do not unauthorized products for sexual enhancement due to potential health risks

Health Canada is advising consumers not to use the unauthorized natural health products Zimaxx, Actra-Rx, 4Everon, Vigor-25 and Nasutra because they are adulterated with pharmaceutical ingredients that should only be used under medical supervision. The use of these products could pose a serious health risk, especially for patients with existing medical conditions such as heart problems, those who are taking heart medications, or those who may be at risk for strokes.

Health :: Do not unauthorized products for sexual enhancement due to potential health risks

Health :: Vaccine-producing ‘plant-factories’

A research team at the Consejo Superior de Investigaciones Cient?ficas (CSIC) has discovered a new route for the transport of proteins in plant cells, a discovery that will enable the biotechnological design of plant factories. Amongst other applications, these can be used to produce oral vaccines which, upon being ingested, will be able to immunise against diseases. Moreover, this discovery opens the door to the design of protein-manufacturing plants of great interest therapeutically and in the development of vaccine antigens.

Health :: WHO to tackle counterfeit medical products – IMPACT

On 15 November, the World Health Organization (WHO) and its partners will officially launch the first ever International Medical Products Anti-counterfeiting Taskforce (IMPACT) and unveil the global plan to combat counterfeit medical products.

Cancer :: ‘Hair Again’ Gives Cancer Journey Meaning

“Medicine alone is not enough to get you through cancer,” comments Linda Dibblee, breast cancer survivor and winner of the 2006 Lilly Oncology on Canvas International Art Competition and Exhibition. “You have to stay strong and positive through even the darkest times. Having a channel through which you can release your feelings can help you find strength that you never knew you had. For me, painting became my way of expressing all my thoughts, hopes and frustrations, and I truly believe it played a part in helping me beat cancer.”

Diabetes :: Accurate coding is key to preventing potentially serious health complications associated with insulin overdose

Significant errors in insulin dose can result when blood glucose meters are miscoded according to new clinical study. When persons with diabetes use miscoded blood glucose meters to determine how much insulin to take, significant errors in insulin dose can result that may potentially lead to short- and long-term health complications, according to findings of a new study presented at the Sixth Annual Diabetes Technology Meeting in Atlanta, Georgia.

Colorectal Cancer :: Data Available from Two Randomized ERBITUX Studies in Metastatic Colorectal Cancer

ImClone Systems Incorporated (NASDAQ:IMCL) and Bristol-Myers Squibb Company (NYSE:BMY) today announced results from two randomized Phase III trials of ERBITUX(R) (cetuximab) in patients with metastatic colorectal cancer. These are the first large, randomized studies to examine the impact of ERBITUX treatment on overall survival in colon cancer.

Health Care :: Novartis creates new strategic biomedical R&D center in Shanghai

Novartis announced plans to build an integrated biomedical Research & Development center in Shanghai’s Zhangjiang Hi-Tech Park that will become an integral part of the Group’s global research and development network.

Health :: FDA issues approvable letter for Entereg for POI

GlaxoSmithKline (NYSE: GSK) and Adolor Corporation (Nasdaq: ADLR) announced that the Food and Drug Administration (FDA) has issued a letter stating that the new drug application (NDA) for Entereg (alvimopan 12mg) for the management of post operative ileus (POI) is approvable. The FDA has requested 12-month safety data, including analysis of serious cardiovascular events, from study 014 (767905/014), an ongoing safety study in opioid-induced bowel dysfunction (OBD). The FDA also requested a risk management plan as part of the submission.

Health :: Ranbaxy’s Cetirizine Syrup approved in USA by FDA

Ranbaxy Pharmaceuticals Inc. (RPI), a wholly owned subsidiary of Ranbaxy Laboratories Limited (RLL), announced today that RLL has received tentative approval from the U.S. Food and Drug Administration to manufacture and market Cetirizine Hydrochloride Syrup, 5 mg/5 mL. Total annual market sales for Cetirizine Hydrochloride Syrup were $146.3 million (IMS ? MAT: June 2006).